We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




DNA Nanotechnology Boosts Sensitivity of Test Strips

By LabMedica International staff writers
Posted on 21 Apr 2025

Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). More...

These tests are used to quickly detect biomarkers that indicate the presence of specific pathogens or health conditions. Due to their simplicity and cost-effectiveness, rapid tests are widely used for point-of-care diagnostics. However, traditional test strips often struggle to detect essential biomarkers that exist in very small amounts in blood, saliva, or urine. This limitation can result in critical conditions, such as strokes or heart attacks, going undiagnosed in their early stages, even though fast medical intervention is crucial for a favorable recovery. Now, researchers have significantly improved conventional test strips by using DNA origami to create a nanoscale amplifier, enabling the amplification of signals from biomarkers, which can now be enhanced up to 125 times.

A research team from Ludwig Maximilian University of Munich (Munich, Germany) has enhanced these tests by employing DNA origami, an advanced nanotechnology. In DNA origami, DNA is folded—much like the Japanese art of paper folding—into nanoscale structures that can take nearly any shape. The researchers used this technology to build a nanoscale amplifier, which dramatically boosts the sensitivity of LFIAs. Their findings, published in Nature Communications, detail how this approach improves the detection of various biomarkers, such as the heart attack marker cardiac troponin I (cTnI) and the stroke marker neurofilament light chain (NfL).

The new signal amplification system, based on DNA nanotechnology, acts as a molecular amplifier by linking detection antibodies to a precise number of signal-generating labels. This method enhances sensitivity by up to 125 times. It is adaptable to various biomarkers and sample types, including drugs of abuse, making it a flexible solution for improving existing rapid tests. According to the research team, this innovation will pave the way for more sensitive, rapid, and accessible diagnostic tools for both clinical and home-based testing. Additionally, the cost of the molecular amplifier is estimated to be about one cent per test.

“Our technology allows for unparalleled control over the amplification factor, making LFIA tests more reliable and effective for clinical applications,” said lead author Dr. Heini Ijäs. “This innovation has the potential to transform diagnostic testing across a broad range of diseases.”


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Calprotectin Assay
Fecal Calprotectin ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.